SCHEMBL29014773

SCHEMBL29014773

COC(=O)C(O)C(C)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CYP2D6 P10635 1/20 0.45
▸ CTSK P43235 9/20 0.40
▸ CTSS P25774 4/20 0.40
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KLK5 Q9Y337 2/20 0.39
▸ CTSL P07711 2/20 0.38
▸ CTSB P07858 2/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PSENEN Q9NZ42 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13167902 0.84 CYP1A2 (0.50) CA1CA2CA7CYP2D6CTSK
Lithium Ion SCHEMBL25405268 0.84 CA1 (0.45) CA12CA14CA1CA2CA7
SCHEMBL18824918 0.83 CA12 (0.47) CA12CA14CA1CA2CA7
SCHEMBL14199208 0.83 CA1 (0.47) CA12CA14CA1CA2CA7
SCHEMBL4521107 0.83 CA1 (0.47) CA1CA2CA7CYP2D6CTSK
SCHEMBL12516683 0.82 CYP2D6 (0.58) CA12CA14CA1CA2CA7
SCHEMBL24069882 0.82 CA1 (0.57) CA12CA14CA1CA2CA7
SCHEMBL13447409 0.81 CA1 (0.46) CA12CA14CA1CA2CA7
SCHEMBL19102018 0.80 CA1 (0.52) CA12CA14CA1CA2CA7
SCHEMBL23622224 0.80 CA1 (0.52) CA12CA14CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116056697-A 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors 默沙东有限责任公司 2023-05-02 — — CN disclosed
EP-4167994-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-26 — — EP disclosed
Send feedback